Alaunos Therapeutics Inc.: 52-Week High Recently Eclipsed (TCRT)

September 9, 2022 09:31:40

Alaunos Therapeutics Inc. (NASDAQ:TCRT) traded at a new 52-week high today of $3.85. Approximately 130,000 shares have changed hands today, as compared to an average 30-day volume of 2.9 million shares.

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.

Over the past year, Alaunos Therapeutics Inc. has traded in a range of $0.41 to $3.85 and is now at $3.74, 823% above that low.

There is potential upside of 9.7% for shares of Alaunos Therapeutics Inc. based on a current price of $3.74 and an average consensus analyst price target of $4.10.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: